Background

• Autoimmune disease is the 4th largest cause of disability among women in the United States
• Autoimmune disease has an incidence rate of 4% worldwide, or 300 million individuals, and increasing
• IDO1 catalyzes the first, rate-limiting step of the kynurenine pathway, and is highly expressed in antigen-presenting cells (APCs) in inflammatory conditions dominated by interferon γ (IFN-γ)
• Targeting the kynurenine pathway may help control autoimmune and chronic inflammatory diseases, but which kynurenine to target remains unclear
• Unmet Need: Improved understanding of kynurenine pathway to inform targeted therapy for autoimmune diseases